Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is a clinical-stage biopharmaceutical company that has a promising outlook due to its focus on addressing the unmet need for TRD treatment and its strong portfolio of mebufotenin products, particularly GH001 which has shown positive results in Phase 2 trials. The completion of enrollment in Phase 1 trials for both the inhalable and intravenous formulations, as well as a successful offering that boosted the company's cash reserves, are positive indicators of its operational progress. The company's scientific visibility, with posters and presentations at major conferences, and its goal of initiating a global Phase 3 trial in late 2026, further support the positive outlook for GH Research.

Bears say

GH Research is a clinical-stage biopharmaceutical company with a narrow focus on developing treatments for depression using mebufotenin. While their portfolio includes two product candidates, GH001 and GH002, the company's near-term strategic focus remains on GH001 for the treatment of Treatment-Resistant Depression (TRD). While GH002 remains a longer-term option, the company's balance sheet has improved after a recent raise to fund further research and development. The company may face potential risks, including competition from other psychedelics and generic antidepressants, legal challenges to their patents, financial risks from ongoing net losses, and regulatory risks from FDA and DEA approval processes.

GHRS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 6 analysts, GHRS has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.